Screening for albuminuria to assess cardiovascular risk

Rev Med Suisse. 2026 Mar 4;22(952):452-458. doi: 10.53738/REVMED.2026.22.952.48360.ABSTRACTCardio-kidney-metabolic (CKM) syndrome combines cardiac, renal, and metabolic impairments. Albuminuria, as measured by the urine albumin-to-creatinine ratio, is a biomarker of endothelium-glomerular damage pre

R Raphaël Akiba

Controversies in familial dyslipidemias and cardiovascular genetics in 2026

Rev Med Suisse. 2026 Mar 4;22(952):433-437. doi: 10.53738/REVMED.2026.22.952.48348.ABSTRACTAlthough familial dyslipidemias are rarer than polygenic or more common causes, it is important not to overlook them, as they are associated with an increased risk of premature cardiovascular disease. Early sc

M Maximilien Fleury

Mitochondria-associated programmed cell death in pancreatic β cell of T2DM

Apoptosis. 2026 Mar 5;31(3):84. doi: 10.1007/s10495-026-02315-0.ABSTRACTMitochondria, as essential organelles that integrate energy metabolism and intracellular signaling, have recently gained increasing attention in the study of pancreatic β-cell dysfunction in type 2 diabetes mellitus (T2DM). Prog

Y Ying Zhang

Modern treatment of type 2 diabetes: 3 medications and 3 targets

Praxis (Bern 1994). 2026 Feb;115(2):43-44. doi: 10.23785/PRAXIS.2026.02.004.ABSTRACTModern treatment of type 2 diabetes considers the use of three medications in all patients regardless of HbA1c (metformin, SGLT-2i, and GLP-1(+)-RA) as well as achieving three target values (HbA1c, blood pressure, an

P Peter Wiesli

Cardiovascular risk profiles in patients with primary sclerosing cholangitis

Eur J Gastroenterol Hepatol. 2026 Feb 23. doi: 10.1097/MEG.0000000000003146. Online ahead of print.ABSTRACTINTRODUCTION: Chronic inflammation as seen in patients with primary sclerosing cholangitis (PSC) is linked to accelerated development and progression of atherosclerosis. This study aimed to ass

J J A M Sleutjes